Sarvac Limited specializes in organising of stable partnerships between potentially interested manufacturing and distribution companies, research institutions of Russia, CIS and other countries in biotechnology, pharmacology and vaccinology. Sarvac also organizes project management and tehcnologies transfer to Russia, CIS and Cyprus for companies that do not have representative offices.
Sarvac was established in 2010. Since that time, Sarvac has realized several projects on counseling European, US and Asian manufacturers of vaccines on registration and promotion in Russia, Ukraine, Belarus, Kazakhstan and Uzbekistan.
In 2012, through the mediation of Sarvac the technology transfer of inactivated polyomielitis vaccines was carried out from the Dutch vaccines manufacturer Bilthoven Biologicals (Poonawalla Group, India) to the Russian company Nanolek LLC.
In 2015, Sarvac signed an agreement with the Indian manufacturer Cadila Healthcare Ltd (Zydus Cadila) on consulting in the marketing of vaccines for Russia and CIS.
In July 2016 Sarvac obtained an authorization from Seqirus (CSL Group) for promotion of influenza vaccines in Russia and Ukraine.
In August 2016 Sarvac received an authorization from the vaccines manufacturer Valneva for promotion of the vaccines against cholera Dukoral and against Japonese Ensephalitis IXIARO in Russia, CIS and Cyprus.